#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Neural responses to negative outcomes predict success in community-based substance use treatment Background and aims Activation in some specific brain regions has demonstrated promise as prognostic indicators in substance dependent individuals (SDIs) but this issue has not yet been explored in SDIs attending typical of community-based treatment.
1-1	0-6	Neural	_
1-2	7-16	responses	_
1-3	17-19	to	_
1-4	20-28	negative	_
1-5	29-37	outcomes	_
1-6	38-45	predict	_
1-7	46-53	success	_
1-8	54-56	in	_
1-9	57-72	community-based	_
1-10	73-82	substance	_
1-11	83-86	use	_
1-12	87-96	treatment	_
1-13	97-107	Background	_
1-14	108-111	and	_
1-15	112-116	aims	_
1-16	117-127	Activation	_
1-17	128-130	in	_
1-18	131-135	some	_
1-19	136-144	specific	_
1-20	145-150	brain	_
1-21	151-158	regions	_
1-22	159-162	has	_
1-23	163-175	demonstrated	_
1-24	176-183	promise	_
1-25	184-186	as	_
1-26	187-197	prognostic	_
1-27	198-208	indicators	_
1-28	209-211	in	_
1-29	212-221	substance	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
1-30	222-231	dependent	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
1-31	232-243	individuals	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
1-32	244-245	(	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
1-33	246-250	SDIs	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
1-34	251-252	)	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
1-35	253-256	but	_
1-36	257-261	this	_
1-37	262-267	issue	_
1-38	268-271	has	_
1-39	272-275	not	_
1-40	276-279	yet	_
1-41	280-284	been	_
1-42	285-293	explored	_
1-43	294-296	in	_
1-44	297-301	SDIs	_
1-45	302-311	attending	_
1-46	312-319	typical	_
1-47	320-322	of	_
1-48	323-338	community-based	_
1-49	339-348	treatment	_
1-50	349-350	.	_

Text=We used a data-driven, exploratory approach to identify brain-based predictors of treatment outcome in a representative community sample of SDIs.
2-1	351-353	We	_
2-2	354-358	used	_
2-3	359-360	a	_
2-4	361-372	data-driven	_
2-5	373-374	,	_
2-6	375-386	exploratory	_
2-7	387-395	approach	_
2-8	396-398	to	_
2-9	399-407	identify	_
2-10	408-419	brain-based	_
2-11	420-430	predictors	_
2-12	431-433	of	_
2-13	434-443	treatment	_
2-14	444-451	outcome	_
2-15	452-454	in	_
2-16	455-456	a	_
2-17	457-471	representative	_
2-18	472-481	community	_
2-19	482-488	sample	_
2-20	489-491	of	_
2-21	492-496	SDIs	_
2-22	497-498	.	_

Text=The predictive utility of brain-based measures was evaluated against clinical indicators, cognitive-behavioral performance, and self-report assessments.
3-1	499-502	The	_
3-2	503-513	predictive	_
3-3	514-521	utility	_
3-4	522-524	of	_
3-5	525-536	brain-based	_
3-6	537-545	measures	_
3-7	546-549	was	_
3-8	550-559	evaluated	_
3-9	560-567	against	_
3-10	568-576	clinical	_
3-11	577-587	indicators	_
3-12	588-589	,	_
3-13	590-610	cognitive-behavioral	_
3-14	611-622	performance	_
3-15	623-624	,	_
3-16	625-628	and	_
3-17	629-640	self-report	_
3-18	641-652	assessments	_
3-19	653-654	.	_

Text=Design Prospective clinical outcome design, evaluating baseline functional magnetic resonance imaging data from the Balloon Analogue Risk Task (BART) as a predictor of 3-month substance use treatment outcomes.
4-1	655-661	Design	_
4-2	662-673	Prospective	_
4-3	674-682	clinical	_
4-4	683-690	outcome	_
4-5	691-697	design	_
4-6	698-699	,	_
4-7	700-710	evaluating	_
4-8	711-719	baseline	_
4-9	720-730	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-10	731-739	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-11	740-749	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-12	750-757	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-13	758-762	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-14	763-767	from	_
4-15	768-771	the	_
4-16	772-779	Balloon	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
4-17	780-788	Analogue	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
4-18	789-793	Risk	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
4-19	794-798	Task	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
4-20	799-800	(	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
4-21	801-805	BART	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
4-22	806-807	)	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
4-23	808-810	as	_
4-24	811-812	a	_
4-25	813-822	predictor	_
4-26	823-825	of	_
4-27	826-833	3-month	_
4-28	834-843	substance	_
4-29	844-847	use	_
4-30	848-857	treatment	_
4-31	858-866	outcomes	_
4-32	867-868	.	_

Text=Setting Community-based substance use programs in Bloomington, Indiana, USA.
5-1	869-876	Setting	_
5-2	877-892	Community-based	_
5-3	893-902	substance	_
5-4	903-906	use	_
5-5	907-915	programs	_
5-6	916-918	in	_
5-7	919-930	Bloomington	_
5-8	931-932	,	_
5-9	933-940	Indiana	_
5-10	941-942	,	_
5-11	943-946	USA	_
5-12	947-948	.	_

Text=Participants Twenty-three SDIs (17 male, ages 18–43) in an intensive outpatient or residential treatment program; abstinent 1–4 weeks at baseline.
6-1	949-961	Participants	_
6-2	962-974	Twenty-three	_
6-3	975-979	SDIs	http://maven.renci.org/NeuroBridge/neurobridge#GravesDisease
6-4	980-981	(	_
6-5	982-984	17	_
6-6	985-989	male	_
6-7	990-991	,	_
6-8	992-996	ages	_
6-9	997-1002	18–43	_
6-10	1003-1004	)	_
6-11	1005-1007	in	_
6-12	1008-1010	an	_
6-13	1011-1020	intensive	_
6-14	1021-1031	outpatient	_
6-15	1032-1034	or	_
6-16	1035-1046	residential	_
6-17	1047-1056	treatment	_
6-18	1057-1064	program	_
6-19	1065-1066	;	_
6-20	1067-1076	abstinent	_
6-21	1077-1080	1–4	_
6-22	1081-1086	weeks	_
6-23	1087-1089	at	_
6-24	1090-1098	baseline	_
6-25	1099-1100	.	_

Text=Measurements Event-related brain response, BART performance, and self-report scores at treatment onset, substance use outcome measure (based on days of use) Findings Using voxel-level predictive modeling and leave-one-out cross-validation, an elevated response to unexpected negative feedback in bilateral amygdala and anterior hippocampus (Amyg/aHipp) at baseline successfully predicted greater substance use over the 3-month study interval (p ≤ 0.006, cluster-corrected).
7-1	1101-1113	Measurements	_
7-2	1114-1127	Event-related	_
7-3	1128-1133	brain	_
7-4	1134-1142	response	_
7-5	1143-1144	,	_
7-6	1145-1149	BART	_
7-7	1150-1161	performance	_
7-8	1162-1163	,	_
7-9	1164-1167	and	_
7-10	1168-1179	self-report	_
7-11	1180-1186	scores	_
7-12	1187-1189	at	_
7-13	1190-1199	treatment	_
7-14	1200-1205	onset	_
7-15	1206-1207	,	_
7-16	1208-1217	substance	_
7-17	1218-1221	use	_
7-18	1222-1229	outcome	_
7-19	1230-1237	measure	_
7-20	1238-1239	(	_
7-21	1240-1245	based	_
7-22	1246-1248	on	_
7-23	1249-1253	days	_
7-24	1254-1256	of	_
7-25	1257-1260	use	_
7-26	1261-1262	)	_
7-27	1263-1271	Findings	_
7-28	1272-1277	Using	_
7-29	1278-1289	voxel-level	_
7-30	1290-1300	predictive	_
7-31	1301-1309	modeling	_
7-32	1310-1313	and	_
7-33	1314-1327	leave-one-out	_
7-34	1328-1344	cross-validation	_
7-35	1345-1346	,	_
7-36	1347-1349	an	_
7-37	1350-1358	elevated	_
7-38	1359-1367	response	_
7-39	1368-1370	to	_
7-40	1371-1381	unexpected	_
7-41	1382-1390	negative	_
7-42	1391-1399	feedback	_
7-43	1400-1402	in	_
7-44	1403-1412	bilateral	_
7-45	1413-1421	amygdala	_
7-46	1422-1425	and	_
7-47	1426-1434	anterior	_
7-48	1435-1446	hippocampus	_
7-49	1447-1448	(	_
7-50	1449-1459	Amyg/aHipp	_
7-51	1460-1461	)	_
7-52	1462-1464	at	_
7-53	1465-1473	baseline	_
7-54	1474-1486	successfully	_
7-55	1487-1496	predicted	_
7-56	1497-1504	greater	_
7-57	1505-1514	substance	_
7-58	1515-1518	use	_
7-59	1519-1523	over	_
7-60	1524-1527	the	_
7-61	1528-1535	3-month	_
7-62	1536-1541	study	_
7-63	1542-1550	interval	_
7-64	1551-1552	(	_
7-65	1553-1554	p	_
7-66	1555-1556	≤	_
7-67	1557-1562	0.006	_
7-68	1563-1564	,	_
7-69	1565-1582	cluster-corrected	_
7-70	1583-1584	)	_
7-71	1585-1586	.	_

Text=This effect was robust to inclusion of significant non-brain-based covariates.
8-1	1587-1591	This	_
8-2	1592-1598	effect	_
8-3	1599-1602	was	_
8-4	1603-1609	robust	_
8-5	1610-1612	to	_
8-6	1613-1622	inclusion	_
8-7	1623-1625	of	_
8-8	1626-1637	significant	_
8-9	1638-1653	non-brain-based	_
8-10	1654-1664	covariates	_
8-11	1665-1666	.	_

Text=A larger response to negative feedback in bilateral Amyg/aHipp was also associated with faster reward-seeking responses after negative feedback (r (23) = −0.544, p = 0.007; r (23) = −0.588, p = 0.003).
9-1	1667-1668	A	_
9-2	1669-1675	larger	_
9-3	1676-1684	response	_
9-4	1685-1687	to	_
9-5	1688-1696	negative	_
9-6	1697-1705	feedback	_
9-7	1706-1708	in	_
9-8	1709-1718	bilateral	_
9-9	1719-1729	Amyg/aHipp	_
9-10	1730-1733	was	_
9-11	1734-1738	also	_
9-12	1739-1749	associated	_
9-13	1750-1754	with	_
9-14	1755-1761	faster	_
9-15	1762-1776	reward-seeking	_
9-16	1777-1786	responses	_
9-17	1787-1792	after	_
9-18	1793-1801	negative	_
9-19	1802-1810	feedback	_
9-20	1811-1812	(	_
9-21	1813-1814	r	_
9-22	1815-1816	(	_
9-23	1817-1819	23	_
9-24	1820-1821	)	_
9-25	1822-1823	=	_
9-26	1824-1830	−0.544	_
9-27	1831-1832	,	_
9-28	1833-1834	p	_
9-29	1835-1836	=	_
9-30	1837-1842	0.007	_
9-31	1843-1844	;	_
9-32	1845-1846	r	_
9-33	1847-1848	(	_
9-34	1849-1851	23	_
9-35	1852-1853	)	_
9-36	1854-1855	=	_
9-37	1856-1862	−0.588	_
9-38	1863-1864	,	_
9-39	1865-1866	p	_
9-40	1867-1868	=	_
9-41	1869-1874	0.003	_
9-42	1875-1876	)	_
9-43	1877-1878	.	_

Text=A model including Amyg/aHipp activation, faster reward-seeking after negative feedback, and significant self-report scores accounted for 45% of the variance in substance use outcomes in our sample.
10-1	1879-1880	A	_
10-2	1881-1886	model	_
10-3	1887-1896	including	_
10-4	1897-1907	Amyg/aHipp	_
10-5	1908-1918	activation	_
10-6	1919-1920	,	_
10-7	1921-1927	faster	_
10-8	1928-1942	reward-seeking	_
10-9	1943-1948	after	_
10-10	1949-1957	negative	_
10-11	1958-1966	feedback	_
10-12	1967-1968	,	_
10-13	1969-1972	and	_
10-14	1973-1984	significant	_
10-15	1985-1996	self-report	_
10-16	1997-2003	scores	_
10-17	2004-2013	accounted	_
10-18	2014-2017	for	_
10-19	2018-2020	45	_
10-20	2021-2022	%	_
10-21	2023-2025	of	_
10-22	2026-2029	the	_
10-23	2030-2038	variance	_
10-24	2039-2041	in	_
10-25	2042-2051	substance	_
10-26	2052-2055	use	_
10-27	2056-2064	outcomes	_
10-28	2065-2067	in	_
10-29	2068-2071	our	_
10-30	2072-2078	sample	_
10-31	2079-2080	.	_

Text=Conclusions An elevated response to unexpected negative feedback in bilateral amygdala and anterior hippocampus (Amyg/aHipp) appears to predict relapse to substance use in people attending community-based treatment.
11-1	2081-2092	Conclusions	_
11-2	2093-2095	An	_
11-3	2096-2104	elevated	_
11-4	2105-2113	response	_
11-5	2114-2116	to	_
11-6	2117-2127	unexpected	_
11-7	2128-2136	negative	_
11-8	2137-2145	feedback	_
11-9	2146-2148	in	_
11-10	2149-2158	bilateral	_
11-11	2159-2167	amygdala	_
11-12	2168-2171	and	_
11-13	2172-2180	anterior	_
11-14	2181-2192	hippocampus	_
11-15	2193-2194	(	_
11-16	2195-2205	Amyg/aHipp	_
11-17	2206-2207	)	_
11-18	2208-2215	appears	_
11-19	2216-2218	to	_
11-20	2219-2226	predict	_
11-21	2227-2234	relapse	_
11-22	2235-2237	to	_
11-23	2238-2247	substance	_
11-24	2248-2251	use	_
11-25	2252-2254	in	_
11-26	2255-2261	people	_
11-27	2262-2271	attending	_
11-28	2272-2287	community-based	_
11-29	2288-2297	treatment	_
11-30	2298-2299	.	_

Text=Methods Design We utilized a prospective clinical outcome design.
12-1	2300-2307	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
12-2	2308-2314	Design	_
12-3	2315-2317	We	_
12-4	2318-2326	utilized	_
12-5	2327-2328	a	_
12-6	2329-2340	prospective	_
12-7	2341-2349	clinical	_
12-8	2350-2357	outcome	_
12-9	2358-2364	design	_
12-10	2365-2366	.	_

Text=Neuroimaging, cognitive-behavioral, and self-report measures were collected at the beginning of treatment and examined as candidate predictors of three-month substance use outcomes.
13-1	2367-2379	Neuroimaging	_
13-2	2380-2381	,	_
13-3	2382-2402	cognitive-behavioral	_
13-4	2403-2404	,	_
13-5	2405-2408	and	_
13-6	2409-2420	self-report	_
13-7	2421-2429	measures	_
13-8	2430-2434	were	_
13-9	2435-2444	collected	_
13-10	2445-2447	at	_
13-11	2448-2451	the	_
13-12	2452-2461	beginning	_
13-13	2462-2464	of	_
13-14	2465-2474	treatment	_
13-15	2475-2478	and	_
13-16	2479-2487	examined	_
13-17	2488-2490	as	_
13-18	2491-2500	candidate	_
13-19	2501-2511	predictors	_
13-20	2512-2514	of	_
13-21	2515-2526	three-month	_
13-22	2527-2536	substance	_
13-23	2537-2540	use	_
13-24	2541-2549	outcomes	_
13-25	2550-2551	.	_

Text=Participants Twenty-six SDIs were enrolled upon engagement with community-based treatment and assessed within 1–4 weeks of self-reported abstinence; a sample of 23 (ages 18–43) was followed for 3 months (see Table 1 for demographic and recruitment data).
14-1	2552-2564	Participants	_
14-2	2565-2575	Twenty-six	_
14-3	2576-2580	SDIs	http://maven.renci.org/NeuroBridge/neurobridge#GravesDisease
14-4	2581-2585	were	_
14-5	2586-2594	enrolled	_
14-6	2595-2599	upon	_
14-7	2600-2610	engagement	_
14-8	2611-2615	with	_
14-9	2616-2631	community-based	_
14-10	2632-2641	treatment	_
14-11	2642-2645	and	_
14-12	2646-2654	assessed	_
14-13	2655-2661	within	_
14-14	2662-2665	1–4	_
14-15	2666-2671	weeks	_
14-16	2672-2674	of	_
14-17	2675-2688	self-reported	_
14-18	2689-2699	abstinence	_
14-19	2700-2701	;	_
14-20	2702-2703	a	_
14-21	2704-2710	sample	_
14-22	2711-2713	of	_
14-23	2714-2716	23	_
14-24	2717-2718	(	_
14-25	2719-2723	ages	_
14-26	2724-2729	18–43	_
14-27	2730-2731	)	_
14-28	2732-2735	was	_
14-29	2736-2744	followed	_
14-30	2745-2748	for	_
14-31	2749-2750	3	_
14-32	2751-2757	months	_
14-33	2758-2759	(	_
14-34	2760-2763	see	_
14-35	2764-2769	Table	_
14-36	2770-2771	1	_
14-37	2772-2775	for	_
14-38	2776-2787	demographic	_
14-39	2788-2791	and	_
14-40	2792-2803	recruitment	_
14-41	2804-2808	data	_
14-42	2809-2810	)	_
14-43	2811-2812	.	_

Text=Participants received treatment-as-usual through one of two abstinence-oriented, community-based addiction treatment programs (one intensive outpatient and one residential program; see Supporting Materials for additional information) and were not receiving replacement pharmacotherapy.
15-1	2813-2825	Participants	_
15-2	2826-2834	received	_
15-3	2835-2853	treatment-as-usual	_
15-4	2854-2861	through	_
15-5	2862-2865	one	_
15-6	2866-2868	of	_
15-7	2869-2872	two	_
15-8	2873-2892	abstinence-oriented	_
15-9	2893-2894	,	_
15-10	2895-2910	community-based	_
15-11	2911-2920	addiction	_
15-12	2921-2930	treatment	_
15-13	2931-2939	programs	_
15-14	2940-2941	(	_
15-15	2942-2945	one	_
15-16	2946-2955	intensive	_
15-17	2956-2966	outpatient	_
15-18	2967-2970	and	_
15-19	2971-2974	one	_
15-20	2975-2986	residential	_
15-21	2987-2994	program	_
15-22	2995-2996	;	_
15-23	2997-3000	see	_
15-24	3001-3011	Supporting	_
15-25	3012-3021	Materials	_
15-26	3022-3025	for	_
15-27	3026-3036	additional	_
15-28	3037-3048	information	_
15-29	3049-3050	)	_
15-30	3051-3054	and	_
15-31	3055-3059	were	_
15-32	3060-3063	not	_
15-33	3064-3073	receiving	_
15-34	3074-3085	replacement	_
15-35	3086-3101	pharmacotherapy	_
15-36	3102-3103	.	_

Text=All met DSM-IV criteria for alcohol, drug, or polysubstance dependence, without history of traumatic brain injury, neurocognitive disorders, Bipolar, or psychotic illness.
16-1	3104-3107	All	_
16-2	3108-3111	met	_
16-3	3112-3118	DSM-IV	_
16-4	3119-3127	criteria	_
16-5	3128-3131	for	_
16-6	3132-3139	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
16-7	3140-3141	,	_
16-8	3142-3146	drug	http://maven.renci.org/NeuroBridge/neurobridge#DrugRelatedDisorder
16-9	3147-3148	,	_
16-10	3149-3151	or	_
16-11	3152-3165	polysubstance	_
16-12	3166-3176	dependence	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
16-13	3177-3178	,	_
16-14	3179-3186	without	_
16-15	3187-3194	history	_
16-16	3195-3197	of	_
16-17	3198-3207	traumatic	_
16-18	3208-3213	brain	_
16-19	3214-3220	injury	_
16-20	3221-3222	,	_
16-21	3223-3237	neurocognitive	_
16-22	3238-3247	disorders	_
16-23	3248-3249	,	_
16-24	3250-3257	Bipolar	_
16-25	3258-3259	,	_
16-26	3260-3262	or	_
16-27	3263-3272	psychotic	_
16-28	3273-3280	illness	_
16-29	3281-3282	.	_

Text=An electronic breathalyzer and 6-panel urine drug screen were conducted at baseline and 3-month follow-up; behavioral signs of intoxication were also evaluated.
17-1	3283-3285	An	_
17-2	3286-3296	electronic	_
17-3	3297-3309	breathalyzer	_
17-4	3310-3313	and	_
17-5	3314-3321	6-panel	_
17-6	3322-3327	urine	_
17-7	3328-3332	drug	_
17-8	3333-3339	screen	_
17-9	3340-3344	were	_
17-10	3345-3354	conducted	_
17-11	3355-3357	at	_
17-12	3358-3366	baseline	_
17-13	3367-3370	and	_
17-14	3371-3378	3-month	_
17-15	3379-3388	follow-up	_
17-16	3389-3390	;	_
17-17	3391-3401	behavioral	_
17-18	3402-3407	signs	_
17-19	3408-3410	of	_
17-20	3411-3423	intoxication	_
17-21	3424-3428	were	_
17-22	3429-3433	also	_
17-23	3434-3443	evaluated	_
17-24	3444-3445	.	_

Text=Assessments were only conducted if blood alcohol content was 0.000 percent by volume, urinalysis was negative for illicit substances, and behavioral signs of intoxication were absent.
18-1	3446-3457	Assessments	_
18-2	3458-3462	were	_
18-3	3463-3467	only	_
18-4	3468-3477	conducted	_
18-5	3478-3480	if	_
18-6	3481-3486	blood	_
18-7	3487-3494	alcohol	_
18-8	3495-3502	content	_
18-9	3503-3506	was	_
18-10	3507-3512	0.000	_
18-11	3513-3520	percent	_
18-12	3521-3523	by	_
18-13	3524-3530	volume	_
18-14	3531-3532	,	_
18-15	3533-3543	urinalysis	_
18-16	3544-3547	was	_
18-17	3548-3556	negative	_
18-18	3557-3560	for	_
18-19	3561-3568	illicit	_
18-20	3569-3579	substances	_
18-21	3580-3581	,	_
18-22	3582-3585	and	_
18-23	3586-3596	behavioral	_
18-24	3597-3602	signs	_
18-25	3603-3605	of	_
18-26	3606-3618	intoxication	_
18-27	3619-3623	were	_
18-28	3624-3630	absent	_
18-29	3631-3632	.	_

Text=Participants provided written informed consent; all methods were approved by the Indiana University Institutional Review Board.
19-1	3633-3645	Participants	_
19-2	3646-3654	provided	_
19-3	3655-3662	written	_
19-4	3663-3671	informed	_
19-5	3672-3679	consent	_
19-6	3680-3681	;	_
19-7	3682-3685	all	_
19-8	3686-3693	methods	_
19-9	3694-3698	were	_
19-10	3699-3707	approved	_
19-11	3708-3710	by	_
19-12	3711-3714	the	_
19-13	3715-3722	Indiana	_
19-14	3723-3733	University	_
19-15	3734-3747	Institutional	_
19-16	3748-3754	Review	_
19-17	3755-3760	Board	_
19-18	3761-3762	.	_

Text=fMRI Acquisition and BART Procedure Imaging data were acquired at baseline and 3-month follow-up using a 32-channel head coil-equipped, Siemens Magnetom Trio 3-Tesla MRI scanner; follow-up data are reported elsewhere.
20-1	3763-3767	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
20-2	3768-3779	Acquisition	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
20-3	3780-3783	and	_
20-4	3784-3788	BART	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
20-5	3789-3798	Procedure	_
20-6	3799-3806	Imaging	_
20-7	3807-3811	data	_
20-8	3812-3816	were	_
20-9	3817-3825	acquired	_
20-10	3826-3828	at	_
20-11	3829-3837	baseline	_
20-12	3838-3841	and	_
20-13	3842-3849	3-month	_
20-14	3850-3859	follow-up	_
20-15	3860-3865	using	_
20-16	3866-3867	a	_
20-17	3868-3878	32-channel	_
20-18	3879-3883	head	_
20-19	3884-3897	coil-equipped	_
20-20	3898-3899	,	_
20-21	3900-3907	Siemens	_
20-22	3908-3916	Magnetom	_
20-23	3917-3921	Trio	_
20-24	3922-3929	3-Tesla	_
20-25	3930-3933	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
20-26	3934-3941	scanner	_
20-27	3942-3943	;	_
20-28	3944-3953	follow-up	_
20-29	3954-3958	data	_
20-30	3959-3962	are	_
20-31	3963-3971	reported	_
20-32	3972-3981	elsewhere	_
20-33	3982-3983	.	_

Text=Echo-planar gradient-echo T2 * -weighted sequences of 240 whole-brain volumes measured the functional blood-oxygen-level-dependent (BOLD) response during two eight-minute blocks of BART (see Figure 1).
21-1	3984-3995	Echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
21-2	3996-4009	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
21-3	4010-4012	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
21-4	4013-4014	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
21-5	4015-4024	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
21-6	4025-4034	sequences	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
21-7	4035-4037	of	_
21-8	4038-4041	240	_
21-9	4042-4053	whole-brain	_
21-10	4054-4061	volumes	_
21-11	4062-4070	measured	_
21-12	4071-4074	the	_
21-13	4075-4085	functional	_
21-14	4086-4114	blood-oxygen-level-dependent	_
21-15	4115-4116	(	_
21-16	4117-4121	BOLD	_
21-17	4122-4123	)	_
21-18	4124-4132	response	_
21-19	4133-4139	during	_
21-20	4140-4143	two	_
21-21	4144-4156	eight-minute	_
21-22	4157-4163	blocks	_
21-23	4164-4166	of	_
21-24	4167-4171	BART	_
21-25	4172-4173	(	_
21-26	4174-4177	see	_
21-27	4178-4184	Figure	_
21-28	4185-4186	1	_
21-29	4187-4188	)	_
21-30	4189-4190	.	_

Text=Acquisition, task, and preprocessing parameters were identical to previous work; details provided in Supporting Information.
22-1	4191-4202	Acquisition	_
22-2	4203-4204	,	_
22-3	4205-4209	task	_
22-4	4210-4211	,	_
22-5	4212-4215	and	_
22-6	4216-4229	preprocessing	_
22-7	4230-4240	parameters	_
22-8	4241-4245	were	_
22-9	4246-4255	identical	_
22-10	4256-4258	to	_
22-11	4259-4267	previous	_
22-12	4268-4272	work	_
22-13	4273-4274	;	_
22-14	4275-4282	details	_
22-15	4283-4291	provided	_
22-16	4292-4294	in	_
22-17	4295-4305	Supporting	_
22-18	4306-4317	Information	_
22-19	4318-4319	.	_

Text=In brief, the BART involved button-press responses to either ‘ Inflate ’ a balloon – incrementally and quasi-exponentially increasing its size and value in parallel with the probability of explosion – or ‘ Redeem ’ it for its current value.
23-1	4320-4322	In	_
23-2	4323-4328	brief	_
23-3	4329-4330	,	_
23-4	4331-4334	the	_
23-5	4335-4339	BART	_
23-6	4340-4348	involved	_
23-7	4349-4361	button-press	_
23-8	4362-4371	responses	_
23-9	4372-4374	to	_
23-10	4375-4381	either	_
23-11	4382-4383	‘	_
23-12	4384-4391	Inflate	_
23-13	4392-4393	’	_
23-14	4394-4395	a	_
23-15	4396-4403	balloon	_
23-16	4404-4405	–	_
23-17	4406-4419	incrementally	_
23-18	4420-4423	and	_
23-19	4424-4443	quasi-exponentially	_
23-20	4444-4454	increasing	_
23-21	4455-4458	its	_
23-22	4459-4463	size	_
23-23	4464-4467	and	_
23-24	4468-4473	value	_
23-25	4474-4476	in	_
23-26	4477-4485	parallel	_
23-27	4486-4490	with	_
23-28	4491-4494	the	_
23-29	4495-4506	probability	_
23-30	4507-4509	of	_
23-31	4510-4519	explosion	_
23-32	4520-4521	–	_
23-33	4522-4524	or	_
23-34	4525-4526	‘	_
23-35	4527-4533	Redeem	_
23-36	4534-4535	’	_
23-37	4536-4538	it	_
23-38	4539-4542	for	_
23-39	4543-4546	its	_
23-40	4547-4554	current	_
23-41	4555-4560	value	_
23-42	4561-4562	.	_

Text=Stimuli were presented using E-Prime (Psychology Software Tools, Pittsburgh, PA); a projector was used for display within the scanner bore.
24-1	4563-4570	Stimuli	_
24-2	4571-4575	were	_
24-3	4576-4585	presented	_
24-4	4586-4591	using	_
24-5	4592-4599	E-Prime	_
24-6	4600-4601	(	_
24-7	4602-4612	Psychology	_
24-8	4613-4621	Software	_
24-9	4622-4627	Tools	_
24-10	4628-4629	,	_
24-11	4630-4640	Pittsburgh	_
24-12	4641-4642	,	_
24-13	4643-4645	PA	_
24-14	4646-4647	)	_
24-15	4648-4649	;	_
24-16	4650-4651	a	_
24-17	4652-4661	projector	_
24-18	4662-4665	was	_
24-19	4666-4670	used	_
24-20	4671-4674	for	_
24-21	4675-4682	display	_
24-22	4683-4689	within	_
24-23	4690-4693	the	_
24-24	4694-4701	scanner	_
24-25	4702-4706	bore	_
24-26	4707-4708	.	_

Text=Trials began with an image of a balloon.
25-1	4709-4715	Trials	_
25-2	4716-4721	began	_
25-3	4722-4726	with	_
25-4	4727-4729	an	_
25-5	4730-4735	image	_
25-6	4736-4738	of	_
25-7	4739-4740	a	_
25-8	4741-4748	balloon	_
25-9	4749-4750	.	_

Text=A red rectangle was presented for 1.5–2.5 seconds, indicating to wait before responding and subsequently turned green, indicating to respond when ready.
26-1	4751-4752	A	_
26-2	4753-4756	red	_
26-3	4757-4766	rectangle	_
26-4	4767-4770	was	_
26-5	4771-4780	presented	_
26-6	4781-4784	for	_
26-7	4785-4792	1.5–2.5	_
26-8	4793-4800	seconds	_
26-9	4801-4802	,	_
26-10	4803-4813	indicating	_
26-11	4814-4816	to	_
26-12	4817-4821	wait	_
26-13	4822-4828	before	_
26-14	4829-4839	responding	_
26-15	4840-4843	and	_
26-16	4844-4856	subsequently	_
26-17	4857-4863	turned	_
26-18	4864-4869	green	_
26-19	4870-4871	,	_
26-20	4872-4882	indicating	_
26-21	4883-4885	to	_
26-22	4886-4893	respond	_
26-23	4894-4898	when	_
26-24	4899-4904	ready	_
26-25	4905-4906	.	_

Text=Participants responded with left or right index fingers (response-mapping counterbalanced across subjects).
27-1	4907-4919	Participants	_
27-2	4920-4929	responded	_
27-3	4930-4934	with	_
27-4	4935-4939	left	_
27-5	4940-4942	or	_
27-6	4943-4948	right	_
27-7	4949-4954	index	_
27-8	4955-4962	fingers	_
27-9	4963-4964	(	_
27-10	4965-4981	response-mapping	_
27-11	4982-4997	counterbalanced	_
27-12	4998-5004	across	_
27-13	5005-5013	subjects	_
27-14	5014-5015	)	_
27-15	5016-5017	.	_

Text=Each balloon sequence began with a balloon worth $0.00.
28-1	5018-5022	Each	_
28-2	5023-5030	balloon	_
28-3	5031-5039	sequence	_
28-4	5040-5045	began	_
28-5	5046-5050	with	_
28-6	5051-5052	a	_
28-7	5053-5060	balloon	_
28-8	5061-5066	worth	_
28-9	5067-5068	$	_
28-10	5069-5073	0.00	_
28-11	5074-5075	.	_

Text=After each response, a jittered delay of 0–6 seconds preceded feedback (‘ Successful_Gamble ’, ‘ Explode ’, ‘ Confirmed_Gain ’) such that the BOLD response could be estimated separately for decision and outcome intervals.
29-1	5076-5081	After	_
29-2	5082-5086	each	_
29-3	5087-5095	response	_
29-4	5096-5097	,	_
29-5	5098-5099	a	_
29-6	5100-5108	jittered	_
29-7	5109-5114	delay	_
29-8	5115-5117	of	_
29-9	5118-5121	0–6	_
29-10	5122-5129	seconds	_
29-11	5130-5138	preceded	_
29-12	5139-5147	feedback	_
29-13	5148-5149	(	_
29-14	5150-5151	‘	_
29-15	5152-5169	Successful_Gamble	_
29-16	5170-5171	’	_
29-17	5172-5173	,	_
29-18	5174-5175	‘	_
29-19	5176-5183	Explode	_
29-20	5184-5185	’	_
29-21	5186-5187	,	_
29-22	5188-5189	‘	_
29-23	5190-5204	Confirmed_Gain	_
29-24	5205-5206	’	_
29-25	5207-5208	)	_
29-26	5209-5213	such	_
29-27	5214-5218	that	_
29-28	5219-5222	the	_
29-29	5223-5227	BOLD	_
29-30	5228-5236	response	_
29-31	5237-5242	could	_
29-32	5243-5245	be	_
29-33	5246-5255	estimated	_
29-34	5256-5266	separately	_
29-35	5267-5270	for	_
29-36	5271-5279	decision	_
29-37	5280-5283	and	_
29-38	5284-5291	outcome	_
29-39	5292-5301	intervals	_
29-40	5302-5303	.	_

Text=‘ Inflate ’ responses could result in either 1) a ‘ Successful_Gamble, ’ whereupon the display was updated with a larger balloon and increased wager value, initiating the next decision or 2) ‘ Explode ’ feedback, indicating loss of the current wager.
30-1	5304-5305	‘	_
30-2	5306-5313	Inflate	_
30-3	5314-5315	’	_
30-4	5316-5325	responses	_
30-5	5326-5331	could	_
30-6	5332-5338	result	_
30-7	5339-5341	in	_
30-8	5342-5348	either	_
30-9	5349-5350	1	_
30-10	5351-5352	)	_
30-11	5353-5354	a	_
30-12	5355-5356	‘	_
30-13	5357-5374	Successful_Gamble	_
30-14	5375-5376	,	_
30-15	5377-5378	’	_
30-16	5379-5388	whereupon	_
30-17	5389-5392	the	_
30-18	5393-5400	display	_
30-19	5401-5404	was	_
30-20	5405-5412	updated	_
30-21	5413-5417	with	_
30-22	5418-5419	a	_
30-23	5420-5426	larger	_
30-24	5427-5434	balloon	_
30-25	5435-5438	and	_
30-26	5439-5448	increased	_
30-27	5449-5454	wager	_
30-28	5455-5460	value	_
30-29	5461-5462	,	_
30-30	5463-5473	initiating	_
30-31	5474-5477	the	_
30-32	5478-5482	next	_
30-33	5483-5491	decision	_
30-34	5492-5494	or	_
30-35	5495-5496	2	_
30-36	5497-5498	)	_
30-37	5499-5500	‘	_
30-38	5501-5508	Explode	_
30-39	5509-5510	’	_
30-40	5511-5519	feedback	_
30-41	5520-5521	,	_
30-42	5522-5532	indicating	_
30-43	5533-5537	loss	_
30-44	5538-5540	of	_
30-45	5541-5544	the	_
30-46	5545-5552	current	_
30-47	5553-5558	wager	_
30-48	5559-5560	.	_

Text=‘ Redeem ’ responses always resulted in ‘ Confirmed_Gain ’ feedback and addition of the balloon value to block winnings (visible at bottom of screen).
31-1	5561-5562	‘	_
31-2	5563-5569	Redeem	_
31-3	5570-5571	’	_
31-4	5572-5581	responses	_
31-5	5582-5588	always	_
31-6	5589-5597	resulted	_
31-7	5598-5600	in	_
31-8	5601-5602	‘	_
31-9	5603-5617	Confirmed_Gain	_
31-10	5618-5619	’	_
31-11	5620-5628	feedback	_
31-12	5629-5632	and	_
31-13	5633-5641	addition	_
31-14	5642-5644	of	_
31-15	5645-5648	the	_
31-16	5649-5656	balloon	_
31-17	5657-5662	value	_
31-18	5663-5665	to	_
31-19	5666-5671	block	_
31-20	5672-5680	winnings	_
31-21	5681-5682	(	_
31-22	5683-5690	visible	_
31-23	5691-5693	at	_
31-24	5694-5700	bottom	_
31-25	5701-5703	of	_
31-26	5704-5710	screen	_
31-27	5711-5712	)	_
31-28	5713-5714	.	_

Text=Participants completed an average of 95 decision trials and 16 balloon sequences per block.
32-1	5715-5727	Participants	_
32-2	5728-5737	completed	_
32-3	5738-5740	an	_
32-4	5741-5748	average	_
32-5	5749-5751	of	_
32-6	5752-5754	95	_
32-7	5755-5763	decision	_
32-8	5764-5770	trials	_
32-9	5771-5774	and	_
32-10	5775-5777	16	_
32-11	5778-5785	balloon	_
32-12	5786-5795	sequences	_
32-13	5796-5799	per	_
32-14	5800-5805	block	_
32-15	5806-5807	.	_

Text=Additional Measures The timeline follow-back procedure was administered at 1-, 2-, and 3-month timepoints to document drug and alcohol use during the study interval.
33-1	5808-5818	Additional	_
33-2	5819-5827	Measures	_
33-3	5828-5831	The	_
33-4	5832-5840	timeline	_
33-5	5841-5852	follow-back	_
33-6	5853-5862	procedure	_
33-7	5863-5866	was	_
33-8	5867-5879	administered	_
33-9	5880-5882	at	_
33-10	5883-5885	1-	_
33-11	5886-5887	,	_
33-12	5888-5890	2-	_
33-13	5891-5892	,	_
33-14	5893-5896	and	_
33-15	5897-5904	3-month	_
33-16	5905-5915	timepoints	_
33-17	5916-5918	to	_
33-18	5919-5927	document	_
33-19	5928-5932	drug	_
33-20	5933-5936	and	_
33-21	5937-5944	alcohol	_
33-22	5945-5948	use	_
33-23	5949-5955	during	_
33-24	5956-5959	the	_
33-25	5960-5965	study	_
33-26	5966-5974	interval	_
33-27	5975-5976	.	_

Text=Narrative details of use (e.g., subjective intoxication) were also acquired.
34-1	5977-5986	Narrative	_
34-2	5987-5994	details	_
34-3	5995-5997	of	_
34-4	5998-6001	use	_
34-5	6002-6003	(	_
34-6	6004-6008	e.g.	_
34-7	6009-6010	,	_
34-8	6011-6021	subjective	_
34-9	6022-6034	intoxication	_
34-10	6035-6036	)	_
34-11	6037-6041	were	_
34-12	6042-6046	also	_
34-13	6047-6055	acquired	_
34-14	6056-6057	.	_

Text=Details of the timeline follow-back procedure, as well as psychodiagnostic, self-report, and cognitive-behavioral assessments are provided in Supporting Information.
35-1	6058-6065	Details	_
35-2	6066-6068	of	_
35-3	6069-6072	the	_
35-4	6073-6081	timeline	_
35-5	6082-6093	follow-back	_
35-6	6094-6103	procedure	_
35-7	6104-6105	,	_
35-8	6106-6108	as	_
35-9	6109-6113	well	_
35-10	6114-6116	as	_
35-11	6117-6133	psychodiagnostic	_
35-12	6134-6135	,	_
35-13	6136-6147	self-report	_
35-14	6148-6149	,	_
35-15	6150-6153	and	_
35-16	6154-6174	cognitive-behavioral	_
35-17	6175-6186	assessments	_
35-18	6187-6190	are	_
35-19	6191-6199	provided	_
35-20	6200-6202	in	_
35-21	6203-6213	Supporting	_
35-22	6214-6225	Information	_
35-23	6226-6227	.	_

Text=fMRI Analysis Imaging data were analyzed using SPM5 and Matlab R2013a.
36-1	6228-6232	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
36-2	6233-6241	Analysis	_
36-3	6242-6249	Imaging	_
36-4	6250-6254	data	_
36-5	6255-6259	were	_
36-6	6260-6268	analyzed	_
36-7	6269-6274	using	_
36-8	6275-6279	SPM5	_
36-9	6280-6283	and	_
36-10	6284-6290	Matlab	_
36-11	6291-6297	R2013a	_
36-12	6298-6299	.	_

Text=BART BOLD responses were estimated using a general linear model with 20 regressors: six motion regressors, two constants, five main effect regressors (‘ Redeem ’, ‘ Inflate ’, ‘ Explode ’, ‘ Successful_Gamble ’, ‘ Confirmed_Gain ’), five parametric modulators representing explosion probability for each event, and 2 parametric modulators representing ‘ Redeem ’ and ‘ Inflate ’ response times (RTs).
37-1	6300-6304	BART	_
37-2	6305-6309	BOLD	_
37-3	6310-6319	responses	_
37-4	6320-6324	were	_
37-5	6325-6334	estimated	_
37-6	6335-6340	using	_
37-7	6341-6342	a	_
37-8	6343-6350	general	_
37-9	6351-6357	linear	_
37-10	6358-6363	model	_
37-11	6364-6368	with	_
37-12	6369-6371	20	_
37-13	6372-6382	regressors	_
37-14	6383-6384	:	_
37-15	6385-6388	six	_
37-16	6389-6395	motion	_
37-17	6396-6406	regressors	_
37-18	6407-6408	,	_
37-19	6409-6412	two	_
37-20	6413-6422	constants	_
37-21	6423-6424	,	_
37-22	6425-6429	five	_
37-23	6430-6434	main	_
37-24	6435-6441	effect	_
37-25	6442-6452	regressors	_
37-26	6453-6454	(	_
37-27	6455-6456	‘	_
37-28	6457-6463	Redeem	_
37-29	6464-6465	’	_
37-30	6466-6467	,	_
37-31	6468-6469	‘	_
37-32	6470-6477	Inflate	_
37-33	6478-6479	’	_
37-34	6480-6481	,	_
37-35	6482-6483	‘	_
37-36	6484-6491	Explode	_
37-37	6492-6493	’	_
37-38	6494-6495	,	_
37-39	6496-6497	‘	_
37-40	6498-6515	Successful_Gamble	_
37-41	6516-6517	’	_
37-42	6518-6519	,	_
37-43	6520-6521	‘	_
37-44	6522-6536	Confirmed_Gain	_
37-45	6537-6538	’	_
37-46	6539-6540	)	_
37-47	6541-6542	,	_
37-48	6543-6547	five	_
37-49	6548-6558	parametric	_
37-50	6559-6569	modulators	_
37-51	6570-6582	representing	_
37-52	6583-6592	explosion	_
37-53	6593-6604	probability	_
37-54	6605-6608	for	_
37-55	6609-6613	each	_
37-56	6614-6619	event	_
37-57	6620-6621	,	_
37-58	6622-6625	and	_
37-59	6626-6627	2	_
37-60	6628-6638	parametric	_
37-61	6639-6649	modulators	_
37-62	6650-6662	representing	_
37-63	6663-6664	‘	_
37-64	6665-6671	Redeem	_
37-65	6672-6673	’	_
37-66	6674-6677	and	_
37-67	6678-6679	‘	_
37-68	6680-6687	Inflate	_
37-69	6688-6689	’	_
37-70	6690-6698	response	_
37-71	6699-6704	times	_
37-72	6705-6706	(	_
37-73	6707-6710	RTs	_
37-74	6711-6712	)	_
37-75	6713-6714	.	_

Text=A canonical hemodynamic response function was used to model event-related signals during decision (i.e., RT) and outcome (i.e., feedback onset) intervals.
38-1	6715-6716	A	_
38-2	6717-6726	canonical	_
38-3	6727-6738	hemodynamic	_
38-4	6739-6747	response	_
38-5	6748-6756	function	_
38-6	6757-6760	was	_
38-7	6761-6765	used	_
38-8	6766-6768	to	_
38-9	6769-6774	model	_
38-10	6775-6788	event-related	_
38-11	6789-6796	signals	_
38-12	6797-6803	during	_
38-13	6804-6812	decision	_
38-14	6813-6814	(	_
38-15	6815-6819	i.e.	_
38-16	6820-6821	,	_
38-17	6822-6824	RT	_
38-18	6825-6826	)	_
38-19	6827-6830	and	_
38-20	6831-6838	outcome	_
38-21	6839-6840	(	_
38-22	6841-6845	i.e.	_
38-23	6846-6847	,	_
38-24	6848-6856	feedback	_
38-25	6857-6862	onset	_
38-26	6863-6864	)	_
38-27	6865-6874	intervals	_
38-28	6875-6876	.	_

Text=Subject was included as a random effect at the second-level.
39-1	6877-6884	Subject	_
39-2	6885-6888	was	_
39-3	6889-6897	included	_
39-4	6898-6900	as	_
39-5	6901-6902	a	_
39-6	6903-6909	random	_
39-7	6910-6916	effect	_
39-8	6917-6919	at	_
39-9	6920-6923	the	_
39-10	6924-6936	second-level	_
39-11	6937-6938	.	_

Text=Contrasts isolated effects associated with negative outcomes over uncertain (‘ Explode – Successful_Gamble ’) and certain gains (‘ Explode – Confirmed_Gain ’), decisions to pursue uncertain gains (‘ Inflate – Redeem ’), and decisions to pursue certain gains (‘ Redeem – Inflate ’), as well as regions in which trial-to-trial fluctuations in BOLD signal correlated with the probability of explosion (i.e.
40-1	6939-6948	Contrasts	_
40-2	6949-6957	isolated	_
40-3	6958-6965	effects	_
40-4	6966-6976	associated	_
40-5	6977-6981	with	_
40-6	6982-6990	negative	_
40-7	6991-6999	outcomes	_
40-8	7000-7004	over	_
40-9	7005-7014	uncertain	_
40-10	7015-7016	(	_
40-11	7017-7018	‘	_
40-12	7019-7026	Explode	_
40-13	7027-7028	–	_
40-14	7029-7046	Successful_Gamble	_
40-15	7047-7048	’	_
40-16	7049-7050	)	_
40-17	7051-7054	and	_
40-18	7055-7062	certain	_
40-19	7063-7068	gains	_
40-20	7069-7070	(	_
40-21	7071-7072	‘	_
40-22	7073-7080	Explode	_
40-23	7081-7082	–	_
40-24	7083-7097	Confirmed_Gain	_
40-25	7098-7099	’	_
40-26	7100-7101	)	_
40-27	7102-7103	,	_
40-28	7104-7113	decisions	_
40-29	7114-7116	to	_
40-30	7117-7123	pursue	_
40-31	7124-7133	uncertain	_
40-32	7134-7139	gains	_
40-33	7140-7141	(	_
40-34	7142-7143	‘	_
40-35	7144-7151	Inflate	_
40-36	7152-7153	–	_
40-37	7154-7160	Redeem	_
40-38	7161-7162	’	_
40-39	7163-7164	)	_
40-40	7165-7166	,	_
40-41	7167-7170	and	_
40-42	7171-7180	decisions	_
40-43	7181-7183	to	_
40-44	7184-7190	pursue	_
40-45	7191-7198	certain	_
40-46	7199-7204	gains	_
40-47	7205-7206	(	_
40-48	7207-7208	‘	_
40-49	7209-7215	Redeem	_
40-50	7216-7217	–	_
40-51	7218-7225	Inflate	_
40-52	7226-7227	’	_
40-53	7228-7229	)	_
40-54	7230-7231	,	_
40-55	7232-7234	as	_
40-56	7235-7239	well	_
40-57	7240-7242	as	_
40-58	7243-7250	regions	_
40-59	7251-7253	in	_
40-60	7254-7259	which	_
40-61	7260-7274	trial-to-trial	_
40-62	7275-7287	fluctuations	_
40-63	7288-7290	in	_
40-64	7291-7295	BOLD	_
40-65	7296-7302	signal	_
40-66	7303-7313	correlated	_
40-67	7314-7318	with	_
40-68	7319-7322	the	_
40-69	7323-7334	probability	_
40-70	7335-7337	of	_
40-71	7338-7347	explosion	_
40-72	7348-7349	(	_
40-73	7350-7353	i.e	_
40-74	7354-7355	.	_

Text=parametric modulators, designated by ‘ * p (Explode) ’).
41-1	7356-7366	parametric	_
41-2	7367-7377	modulators	_
41-3	7378-7379	,	_
41-4	7380-7390	designated	_
41-5	7391-7393	by	_
41-6	7394-7395	‘	_
41-7	7396-7397	*	_
41-8	7398-7399	p	_
41-9	7400-7401	(	_
41-10	7402-7409	Explode	_
41-11	7410-7411	)	_
41-12	7412-7413	’	_
41-13	7414-7415	)	_
41-14	7416-7417	.	_

Text=Using a cluster-forming threshold of p <0.001, clusters of 30 or more voxels with a cluster-corrected p-value of <0.05, were identified as regions of interest (ROIs).
42-1	7418-7423	Using	_
42-2	7424-7425	a	_
42-3	7426-7441	cluster-forming	_
42-4	7442-7451	threshold	_
42-5	7452-7454	of	_
42-6	7455-7456	p	_
42-7	7457-7458	<	_
42-8	7459-7464	0.001	_
42-9	7465-7466	,	_
42-10	7467-7475	clusters	_
42-11	7476-7478	of	_
42-12	7479-7481	30	_
42-13	7482-7484	or	_
42-14	7485-7489	more	_
42-15	7490-7496	voxels	_
42-16	7497-7501	with	_
42-17	7502-7503	a	_
42-18	7504-7521	cluster-corrected	_
42-19	7522-7529	p-value	_
42-20	7530-7532	of	_
42-21	7533-7534	<	_
42-22	7535-7539	0.05	_
42-23	7540-7541	,	_
42-24	7542-7546	were	_
42-25	7547-7557	identified	_
42-26	7558-7560	as	_
42-27	7561-7568	regions	_
42-28	7569-7571	of	_
42-29	7572-7580	interest	_
42-30	7581-7582	(	_
42-31	7583-7587	ROIs	_
42-32	7588-7589	)	_
42-33	7590-7591	.	_

Text=The cluster-extent threshold was determined using AFNI ’ s 3dClustSim to provide a type I error rate of α = 0.005.
43-1	7592-7595	The	_
43-2	7596-7610	cluster-extent	_
43-3	7611-7620	threshold	_
43-4	7621-7624	was	_
43-5	7625-7635	determined	_
43-6	7636-7641	using	_
43-7	7642-7646	AFNI	_
43-8	7647-7648	’	_
43-9	7649-7650	s	_
43-10	7651-7661	3dClustSim	_
43-11	7662-7664	to	_
43-12	7665-7672	provide	_
43-13	7673-7674	a	_
43-14	7675-7679	type	_
43-15	7680-7681	I	_
43-16	7682-7687	error	_
43-17	7688-7692	rate	_
43-18	7693-7695	of	_
43-19	7696-7697	α	_
43-20	7698-7699	=	_
43-21	7700-7705	0.005	_
43-22	7706-7707	.	_

Text=Two participants were excluded from the second-level ‘ Explode * p (Explode) ’ contrast because low explosion frequency precluded unique specification in the first-level general linear model.
44-1	7708-7711	Two	_
44-2	7712-7724	participants	_
44-3	7725-7729	were	_
44-4	7730-7738	excluded	_
44-5	7739-7743	from	_
44-6	7744-7747	the	_
44-7	7748-7760	second-level	_
44-8	7761-7762	‘	_
44-9	7763-7770	Explode	_
44-10	7771-7772	*	_
44-11	7773-7774	p	_
44-12	7775-7776	(	_
44-13	7777-7784	Explode	_
44-14	7785-7786	)	_
44-15	7787-7788	’	_
44-16	7789-7797	contrast	_
44-17	7798-7805	because	_
44-18	7806-7809	low	_
44-19	7810-7819	explosion	_
44-20	7820-7829	frequency	_
44-21	7830-7839	precluded	_
44-22	7840-7846	unique	_
44-23	7847-7860	specification	_
44-24	7861-7863	in	_
44-25	7864-7867	the	_
44-26	7868-7879	first-level	_
44-27	7880-7887	general	_
44-28	7888-7894	linear	_
44-29	7895-7900	model	_
44-30	7901-7902	.	_

Text=Whole-brain correlational analyses were conducted for each contrast to identify regions in which task-related activity was associated with substance use during the study interval.
45-1	7903-7914	Whole-brain	_
45-2	7915-7928	correlational	_
45-3	7929-7937	analyses	_
45-4	7938-7942	were	_
45-5	7943-7952	conducted	_
45-6	7953-7956	for	_
45-7	7957-7961	each	_
45-8	7962-7970	contrast	_
45-9	7971-7973	to	_
45-10	7974-7982	identify	_
45-11	7983-7990	regions	_
45-12	7991-7993	in	_
45-13	7994-7999	which	_
45-14	8000-8012	task-related	_
45-15	8013-8021	activity	_
45-16	8022-8025	was	_
45-17	8026-8036	associated	_
45-18	8037-8041	with	_
45-19	8042-8051	substance	_
45-20	8052-8055	use	_
45-21	8056-8062	during	_
45-22	8063-8066	the	_
45-23	8067-8072	study	_
45-24	8073-8081	interval	_
45-25	8082-8083	.	_

Text=A substance use metric (SUM) was calculated from timeline follow-back data for each participant, representing incidents of drug and alcohol use during the study, weighted by presence/absence of intoxication; 1 a log-odds transformation was applied prior to analysis.
46-1	8084-8085	A	_
46-2	8086-8095	substance	_
46-3	8096-8099	use	_
46-4	8100-8106	metric	_
46-5	8107-8108	(	_
46-6	8109-8112	SUM	_
46-7	8113-8114	)	_
46-8	8115-8118	was	_
46-9	8119-8129	calculated	_
46-10	8130-8134	from	_
46-11	8135-8143	timeline	_
46-12	8144-8155	follow-back	_
46-13	8156-8160	data	_
46-14	8161-8164	for	_
46-15	8165-8169	each	_
46-16	8170-8181	participant	_
46-17	8182-8183	,	_
46-18	8184-8196	representing	_
46-19	8197-8206	incidents	_
46-20	8207-8209	of	_
46-21	8210-8214	drug	_
46-22	8215-8218	and	_
46-23	8219-8226	alcohol	_
46-24	8227-8230	use	_
46-25	8231-8237	during	_
46-26	8238-8241	the	_
46-27	8242-8247	study	_
46-28	8248-8249	,	_
46-29	8250-8258	weighted	_
46-30	8259-8261	by	_
46-31	8262-8278	presence/absence	_
46-32	8279-8281	of	_
46-33	8282-8294	intoxication	_
46-34	8295-8296	;	_
46-35	8297-8298	1	_
46-36	8299-8300	a	_
46-37	8301-8309	log-odds	_
46-38	8310-8324	transformation	_
46-39	8325-8328	was	_
46-40	8329-8336	applied	_
46-41	8337-8342	prior	_
46-42	8343-8345	to	_
46-43	8346-8354	analysis	_
46-44	8355-8356	.	_

Text=This approach was chosen to better capture variability in substance use outcomes within the study sample (see Supporting Information).
47-1	8357-8361	This	_
47-2	8362-8370	approach	_
47-3	8371-8374	was	_
47-4	8375-8381	chosen	_
47-5	8382-8384	to	_
47-6	8385-8391	better	_
47-7	8392-8399	capture	_
47-8	8400-8411	variability	_
47-9	8412-8414	in	_
47-10	8415-8424	substance	_
47-11	8425-8428	use	_
47-12	8429-8437	outcomes	_
47-13	8438-8444	within	_
47-14	8445-8448	the	_
47-15	8449-8454	study	_
47-16	8455-8461	sample	_
47-17	8462-8463	(	_
47-18	8464-8467	see	_
47-19	8468-8478	Supporting	_
47-20	8479-8490	Information	_
47-21	8491-8492	)	_
47-22	8493-8494	.	_

Text=Next, voxel-level predictive modeling and leave-one-out cross-validation were used to identify ROIs predictive of substance use outcomes and compare performance of models based on brain- and/or non-brain-based predictors (see Supporting Information for details).
48-1	8495-8499	Next	_
48-2	8500-8501	,	_
48-3	8502-8513	voxel-level	_
48-4	8514-8524	predictive	_
48-5	8525-8533	modeling	_
48-6	8534-8537	and	_
48-7	8538-8551	leave-one-out	_
48-8	8552-8568	cross-validation	_
48-9	8569-8573	were	_
48-10	8574-8578	used	_
48-11	8579-8581	to	_
48-12	8582-8590	identify	_
48-13	8591-8595	ROIs	_
48-14	8596-8606	predictive	_
48-15	8607-8609	of	_
48-16	8610-8619	substance	_
48-17	8620-8623	use	_
48-18	8624-8632	outcomes	_
48-19	8633-8636	and	_
48-20	8637-8644	compare	_
48-21	8645-8656	performance	_
48-22	8657-8659	of	_
48-23	8660-8666	models	_
48-24	8667-8672	based	_
48-25	8673-8675	on	_
48-26	8676-8682	brain-	_
48-27	8683-8689	and/or	_
48-28	8690-8705	non-brain-based	_
48-29	8706-8716	predictors	_
48-30	8717-8718	(	_
48-31	8719-8722	see	_
48-32	8723-8733	Supporting	_
48-33	8734-8745	Information	_
48-34	8746-8749	for	_
48-35	8750-8757	details	_
48-36	8758-8759	)	_
48-37	8760-8761	.	_

Text=Briefly, linear regression was applied with cross-validation on a voxel-by-voxel basis.
49-1	8762-8769	Briefly	_
49-2	8770-8771	,	_
49-3	8772-8778	linear	_
49-4	8779-8789	regression	_
49-5	8790-8793	was	_
49-6	8794-8801	applied	_
49-7	8802-8806	with	_
49-8	8807-8823	cross-validation	_
49-9	8824-8826	on	_
49-10	8827-8828	a	_
49-11	8829-8843	voxel-by-voxel	_
49-12	8844-8849	basis	_
49-13	8850-8851	.	_

Text=Clusters wherein constituent voxels yielded predicted SUM values for left-out participants that strongly correlated with actual SUM values were targeted for further investigation.
50-1	8852-8860	Clusters	_
50-2	8861-8868	wherein	_
50-3	8869-8880	constituent	_
50-4	8881-8887	voxels	_
50-5	8888-8895	yielded	_
50-6	8896-8905	predicted	_
50-7	8906-8909	SUM	_
50-8	8910-8916	values	_
50-9	8917-8920	for	_
50-10	8921-8929	left-out	_
50-11	8930-8942	participants	_
50-12	8943-8947	that	_
50-13	8948-8956	strongly	_
50-14	8957-8967	correlated	_
50-15	8968-8972	with	_
50-16	8973-8979	actual	_
50-17	8980-8983	SUM	_
50-18	8984-8990	values	_
50-19	8991-8995	were	_
50-20	8996-9004	targeted	_
50-21	9005-9008	for	_
50-22	9009-9016	further	_
50-23	9017-9030	investigation	_
50-24	9031-9032	.	_

Text=Leave-one-out cross-validation was selected for optimism-correction because this approach has been recommended for small neuroimaging datasets and used in similar work with a comparable sample size.
51-1	9033-9046	Leave-one-out	_
51-2	9047-9063	cross-validation	_
51-3	9064-9067	was	_
51-4	9068-9076	selected	_
51-5	9077-9080	for	_
51-6	9081-9100	optimism-correction	_
51-7	9101-9108	because	_
51-8	9109-9113	this	_
51-9	9114-9122	approach	_
51-10	9123-9126	has	_
51-11	9127-9131	been	_
51-12	9132-9143	recommended	_
51-13	9144-9147	for	_
51-14	9148-9153	small	_
51-15	9154-9166	neuroimaging	_
51-16	9167-9175	datasets	_
51-17	9176-9179	and	_
51-18	9180-9184	used	_
51-19	9185-9187	in	_
51-20	9188-9195	similar	_
51-21	9196-9200	work	_
51-22	9201-9205	with	_
51-23	9206-9207	a	_
51-24	9208-9218	comparable	_
51-25	9219-9225	sample	_
51-26	9226-9230	size	_
51-27	9231-9232	.	_

Text=Predictive analysis of binary treatment outcomes was also conducted using Receiver Operating Characteristic curves and is described in Supporting Information and Figure S1.
52-1	9233-9243	Predictive	_
52-2	9244-9252	analysis	_
52-3	9253-9255	of	_
52-4	9256-9262	binary	_
52-5	9263-9272	treatment	_
52-6	9273-9281	outcomes	_
52-7	9282-9285	was	_
52-8	9286-9290	also	_
52-9	9291-9300	conducted	_
52-10	9301-9306	using	_
52-11	9307-9315	Receiver	_
52-12	9316-9325	Operating	_
52-13	9326-9340	Characteristic	_
52-14	9341-9347	curves	_
52-15	9348-9351	and	_
52-16	9352-9354	is	_
52-17	9355-9364	described	_
52-18	9365-9367	in	_
52-19	9368-9378	Supporting	_
52-20	9379-9390	Information	_
52-21	9391-9394	and	_
52-22	9395-9401	Figure	_
52-23	9402-9404	S1	_
52-24	9405-9406	.	_

Text=Analysis of Cognitive-behavioral and Self-Report Measures Pearson correlations with the substance use outcome variable (i.e., SUM) were calculated for each measure.
53-1	9407-9415	Analysis	_
53-2	9416-9418	of	_
53-3	9419-9439	Cognitive-behavioral	_
53-4	9440-9443	and	_
53-5	9444-9455	Self-Report	_
53-6	9456-9464	Measures	_
53-7	9465-9472	Pearson	_
53-8	9473-9485	correlations	_
53-9	9486-9490	with	_
53-10	9491-9494	the	_
53-11	9495-9504	substance	_
53-12	9505-9508	use	_
53-13	9509-9516	outcome	_
53-14	9517-9525	variable	_
53-15	9526-9527	(	_
53-16	9528-9532	i.e.	_
53-17	9533-9534	,	_
53-18	9535-9538	SUM	_
53-19	9539-9540	)	_
53-20	9541-9545	were	_
53-21	9546-9556	calculated	_
53-22	9557-9560	for	_
53-23	9561-9565	each	_
53-24	9566-9573	measure	_
53-25	9574-9575	.	_

Text=Paired t-tests and repeated measures analysis of variance (ANOVA) were utilized for comparisons between conditions, as necessary.
54-1	9576-9582	Paired	_
54-2	9583-9590	t-tests	_
54-3	9591-9594	and	_
54-4	9595-9603	repeated	_
54-5	9604-9612	measures	_
54-6	9613-9621	analysis	_
54-7	9622-9624	of	_
54-8	9625-9633	variance	_
54-9	9634-9635	(	_
54-10	9636-9641	ANOVA	_
54-11	9642-9643	)	_
54-12	9644-9648	were	_
54-13	9649-9657	utilized	_
54-14	9658-9661	for	_
54-15	9662-9673	comparisons	_
54-16	9674-9681	between	_
54-17	9682-9692	conditions	_
54-18	9693-9694	,	_
54-19	9695-9697	as	_
54-20	9698-9707	necessary	_
54-21	9708-9709	.	_

Text=Statistics were computed in SPSS.
55-1	9710-9720	Statistics	_
55-2	9721-9725	were	_
55-3	9726-9734	computed	_
55-4	9735-9737	in	_
55-5	9738-9742	SPSS	_
55-6	9743-9744	.	_

Text=Self-report and behavioral findings for cognitive-behavioral tasks other than BART are summarized in Supporting Information and Table S1.
56-1	9745-9756	Self-report	_
56-2	9757-9760	and	_
56-3	9761-9771	behavioral	_
56-4	9772-9780	findings	_
56-5	9781-9784	for	_
56-6	9785-9805	cognitive-behavioral	_
56-7	9806-9811	tasks	_
56-8	9812-9817	other	_
56-9	9818-9822	than	_
56-10	9823-9827	BART	_
56-11	9828-9831	are	_
56-12	9832-9842	summarized	_
56-13	9843-9845	in	_
56-14	9846-9856	Supporting	_
56-15	9857-9868	Information	_
56-16	9869-9872	and	_
56-17	9873-9878	Table	_
56-18	9879-9881	S1	_
56-19	9882-9883	.	_

